Serious adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1 [0.94, 1.07]
Studies not reported
Moderate
Non‐vertebral fractures · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes non‐vertebral fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.54 [0.22, 1.35]
Studies not reported
Very low
Hip Fracture · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Wrist fractures · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in wrist fractures compared with placebo (low certainty).
1 finding from 1 review
RR 0.48 [0.03, 7.5]
Studies not reported
Low
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.67 [0.38, 1.18]
Studies not reported
Low
Serious adverse events · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 0.74 [0.42, 1.3]
Studies not reported
Very low
Clinical vertebral fractures · pPostmenopausal women at higher risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Non‐vertebral fractures · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day probably leads to lower non‐vertebral fractures compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.8 [0.72, 0.9]
Studies not reported
Moderate
Hip Fracture · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day may leads to lower hip fractures compared with placebo (low certainty).
1 finding from 1 review
RR 0.73 [0.56, 0.94]
Studies not reported
Low
Pain · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Physical function · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Quality of life · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Participant‐reported global assessment · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Radiographic joint changes · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Adverse events · Patients with osteoarthritis of the knee or hip
Summary of findings table ‐ Adjunctive therapies in addition to… showed no clear difference in adverse events compared with placebo adjunctive therapies (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Mean change in pain from baseline (0‐ to 10‐point scale, 0 is no pain) at 8–16 weeks · predominantly knee osteoarthritis
Antidepressant showed no clear difference in mean change in pain from baseline (0‐ to 10‐point scale, 0 is no… compared with placebo (high certainty).
1 finding from 1 review
At least 50% reduction in pain · predominantly knee osteoarthritis
Antidepressant leads to higher responder rate: ≥ 50% reduction in 24‐hour mean pain compared with placebo (high certainty).
1 finding from 1 review
Physical function · predominantly knee osteoarthritis
Antidepressant showed no clear difference in mean change in physical function from baseline (0–100 WOMAC Total… compared with placebo (high certainty).
1 finding from 1 review
Quality of life (EuroQol, scale −0.11 to 1.0 where a score of 1.0 indicates perfect health) between 0 and 14 weeks · predominantly knee osteoarthritis
Antidepressant probably leads to higher quality of life (EuroQol, scale −0.11 to 1.0 where a score of 1.0… compared with placebo (moderate certainty).
1 finding from 1 review